×

Sandoz Canada launches new multi-platform application to show real-time availability of its injectable medicines

Version française

BOUCHERVILLE, Quebec, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Sandoz Canada, which established a milestone in transparency by providing the first national report on availability of injectable medicines, is innovating once again with the launch of a brand new multi-platform application, which allows healthcare professionals to have this crucial information at their fingertips.

With just one click on their smartphone, tablet or PC, the Sandoz Pro app (sandozpro.sandoz.ca) allows users to view information on availability of injectable medicines. This new tool is designed for healthcare professionals and buyers who want to make the most of their time, as it helps them plan their injectable drug supplies and make informed decisions at all times.

The tool is simple to use: just enter the product name or code and the search engine will provide the medicine's availability status.

The application can be downloaded from the Apple Store and Google Play and is also available at sandoz.ca. This is the first phase in the evolution of Sandoz Pro. The tool is upgradeable and Sandoz Canada will be adding new information and features over time based on user feedback.

"With this new mobile app, we're meeting the needs of clients who want a supply of injectable medicines, thereby facilitating sustainable access to affordable healthcare for the patient. This first in the Canadian pharmaceutical industry shows just how committed Sandoz Canada is to maintaining its position as a leader in transparency and information sharing," said Michel Robidoux, President and General Manager, Sandoz Canada.

Disclaimer

The foregoing release may contain forward-looking statements that can be identified by terminology such as "new", "the first" and "pioneer", or similar expressions, or by express or implied discussions regarding future sales of the above-mentioned products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with the above-mentioned products to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the above-mentioned products will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. In particular, management's expectations regarding commercialization of the above-mentioned products could be affected by, among other things, additional analysis of clinical data in respect of the above-mentioned products, new clinical data, unexpected clinical trial results, unexpected regulatory actions or delays or government regulation generally, the company's ability to obtain or maintain patent or other proprietary intellectual property protection, competition in general, increased government, industry, and general public pricing pressures, and other risks and factors referred to in the Form 20-F filed by Novartis with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz Canada

Established in Boucherville, Quebec, Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis. A leader in its field, Sandoz Canada develops, produces, markets and distributes a wide range of generic products used, among others, in anesthesia, infectious diseases, oncology, dermatology, cardiology, and pain management. The Boucherville manufacturing plant specializes in the production of key injectable products.

About Sandoz

Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.

The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.

Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.

In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).

Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

-30-

CONTACT: For further information: Sandoz Canada Annick Lambert +1 450 641 4903 ext. 2964 annick.lambert@sandoz.com Sandoz Global Communications Chris Lewis +49 8024 476 1906 chris.lewis@sandoz.com

Source:Sandoz Canada

More From Press Releases